ArticleClinical cardiology2026
Efficacy and Safety of Catheter Ablation for Atrial Arrhythmias in Solid Organ Transplant Recipients: A Single-Center Experience.
Article in Clinical cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAtrial arrhythmias are common among solid organ transplant recipients and independently associated with increased morbidity, mortality, and impaired graft survival. Pharmacological management is substantially limited by interactions with immunosuppressive therapy. Despite growing clinical need, data on the feasibility, safety, and efficacy of catheter ablation in this population remain scarce.
methodsSingle-center, retrospective, matched cohort study. All consecutive solid organ transplant recipients who underwent catheter ablation of symptomatic left atrial arrhythmias between July 2021 and June 2024 were included. Each was matched 1:2 to non-transplant controls by age, sex, BMI, arrhythmia type, and ablation modality. All procedures were performed using contemporary techniques: pulsed field ablation (PFA) or very high-power short-duration (vHPSD) radiofrequency ablation.
resultsSixty-six patients were included: 22 transplant recipients and 44 matched controls. Arrhythmia-free survival at 12 months after a 2-month blanking period was 68.2% versus 76.2% (p = 0.49; HR 1.57, 95% CI 0.60-4.12). Periprocedural complications occurred in 9.1% versus 4.6% (p = 0.60); no cases of stroke, cardiac tamponade, or access site complications requiring surgical intervention were recorded in either group. In the kidney transplant subgroup (n = 17), eGFR remained stable at 12 months (41.8 ± 12.1 vs. 43.8 ± 15.3 mL/min/1.73 m², p = 0.34), with no clinically significant decline in renal function observed.
conclusionCatheter ablation for complex atrial arrhythmias in solid organ transplant recipients was feasible using contemporary ablation techniques, without major procedural complications, and no excess safety or efficacy signal was observed at 12 months relative to matched controls. Prospective multicentre studies are needed to confirm these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.